Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
Authors:
Open Access
- 21 November 2022
- journal article
- research article
- Published by Elsevier in Surgical Oncology
- Vol. 45, 101885
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast CancerJAMA Oncology, 2016
- Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)Annals of Surgical Oncology, 2014
- The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerClinical Cancer Research, 2014
- Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancerInternational Journal of Clinical Oncology, 2013
- A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment responseBreast Cancer Research and Treatment, 2011
- The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancerBreast Cancer Research and Treatment, 2010
- 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patientsThe Breast, 2009
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor CharacteristicsJNCI: Journal of the National Cancer Institute, 2008
- Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozoleBritish Journal of Cancer, 2006
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002